Lorrin Yee

1.2k total citations
37 papers, 1.0k citations indexed

About

Lorrin Yee is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lorrin Yee has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lorrin Yee's work include Cancer Treatment and Pharmacology (7 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Erythropoietin and Anemia Treatment (5 papers). Lorrin Yee is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Erythropoietin and Anemia Treatment (5 papers). Lorrin Yee collaborates with scholars based in United States, Spain and United Kingdom. Lorrin Yee's co-authors include Jean L. Grem, Carmen J. Allegra, Patricia LoRusso, Chris H. Takimoto, Lee S. Schwartzberg, Antonio Calles, Irene Braña, Thomas A. Puchalski, Carla J. de Boer and Josep Tabernero and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Lorrin Yee

37 papers receiving 991 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lorrin Yee United States	17	514	446	217	134	128	37	1.0k
Songfu Jiang China	18	418 0.8×	361 0.8×	205 0.9×	251 1.9×	55 0.4×	61	861
K Nakanishi Japan	19	189 0.4×	350 0.8×	164 0.8×	65 0.5×	133 1.0×	61	988
Theresa A. Mays United States	10	477 0.9×	773 1.7×	126 0.6×	65 0.5×	218 1.7×	15	1.2k
Jie Ding China	16	205 0.4×	604 1.4×	197 0.9×	115 0.9×	178 1.4×	57	1.2k
Donnah Jones United States	12	280 0.5×	166 0.4×	177 0.8×	70 0.5×	221 1.7×	14	740
M. Ravic United Kingdom	14	398 0.8×	299 0.7×	198 0.9×	57 0.4×	92 0.7×	36	973
Chung-Tsen Hsueh United States	19	556 1.1×	416 0.9×	87 0.4×	73 0.5×	305 2.4×	55	1.2k
Stefan C. Grant United States	22	786 1.5×	524 1.2×	292 1.3×	50 0.4×	372 2.9×	45	1.4k
Aneeta Patel United States	25	548 1.1×	716 1.6×	183 0.8×	67 0.5×	127 1.0×	56	1.7k
Ramprasad Srinivasan United States	16	213 0.4×	353 0.8×	369 1.7×	317 2.4×	127 1.0×	34	1.2k

Countries citing papers authored by Lorrin Yee

Since Specialization

Citations

This map shows the geographic impact of Lorrin Yee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorrin Yee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorrin Yee more than expected).

Fields of papers citing papers by Lorrin Yee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorrin Yee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorrin Yee. The network helps show where Lorrin Yee may publish in the future.

Co-authorship network of co-authors of Lorrin Yee

This figure shows the co-authorship network connecting the top 25 collaborators of Lorrin Yee. A scholar is included among the top collaborators of Lorrin Yee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorrin Yee. Lorrin Yee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Calvo, Emiliano, Analía Azaro, Jordi Rodón, et al.. (2017). Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Investigational New Drugs. 36(3). 476–486. 2 indexed citations

Braña, Irene, Antonio Calles, Patricia LoRusso, et al.. (2014). Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Targeted Oncology. 10(1). 111–123. 179 indexed citations

LoRusso, Patricia, Pasi A. Jänne, Moacyr Oliveira, et al.. (2013). Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(11). 3078–3087. 74 indexed citations

Keedy, Vicki L., Pasi A. Jänne, Lorrin Yee, et al.. (2011). A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3026–3026. 7 indexed citations

Schwartzberg, Lee S., Ronald L. Burkes, B. Mirtsching, et al.. (2010). Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. BMC Cancer. 10(1). 581–581. 7 indexed citations

Rosen, Peter J., Christopher J. Sweeney, Darrin M. Beaupre, et al.. (2010). A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(9). 2677–2687. 60 indexed citations

Quinn, David I., John Nemunaitis, Jyotsna Fuloria, et al.. (2009). Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma. Clinical Pharmacokinetics. 48(3). 199–209. 30 indexed citations

Mita, Monica, Lorrin Yee, K. Papadopoulos, et al.. (2008). 42 POSTER NPI-2358 (a novel vascular disrupting agent) Phase 1 dose escalation trial with an RP2D cohort. European Journal of Cancer Supplements. 6(12). 17–17. 1 indexed citations

LoRusso, Patricia, Lorrin Yee, K. Papadopoulos, et al.. (2007). Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. Molecular Cancer Therapeutics. 6. 1 indexed citations

10.

Schwartzberg, Lee S., Lorrin Yee, B. Mirtsching, et al.. (2007). A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. 5. 22–23. 1 indexed citations

11.

Senecal, Frank M., Lorrin Yee, Nashat Gabrail, et al.. (2005). Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000 U Weekly. Clinical Breast Cancer. 6(5). 446–454. 20 indexed citations

12.

Schwartzberg, Lee S., Lorrin Yee, Frank M. Senecal, et al.. (2004). A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer. The Oncologist. 9(6). 696–707. 80 indexed citations

13.

Schwartzberg, L., Lorrin Yee, Francis M. Senecal, et al.. (2004). Darbepoetin alfa (DA) 200 mcg every 2 weeks (Q2W) vs epoetin alfa (Epo) 40,000 U weekly (QW) in anemic patients (pts) receiving chemotherapy (ctx). Journal of Clinical Oncology. 22(14_suppl). 8063–8063. 2 indexed citations

14.

Grem, Jean L., Lorrin Yee, Barbara Schüler, et al.. (2001). N-(phosphonacetyl)-l-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma. Annals of Oncology. 12(11). 1581–1587. 2 indexed citations

15.

Yee, Lorrin, Edward Chu, Shih‐Hsi Chu, et al.. (1998). Benzylacyclouridine Enhances 5-Fluorouracil Cytotoxicity against Human Prostate Cancer Cell Lines. Pharmacology. 56(2). 80–91. 6 indexed citations

16.

Chu, Ming, Milton H. Lipsky, Lorrin Yee, et al.. (1998). Predictive Sensitivity of Human Cancer Cells in vivo Using Semipermeable Polysulfone Fibers. Pharmacology. 56(6). 318–326. 5 indexed citations

17.

Finch, Paul W., Lorrin Yee, Ming Chu, et al.. (1997). Inhibition of Growth Factor Mitogenicity and Growth of Tumor Cell Xenografts by a Sulfonated Distamycin A Derivative. Pharmacology. 55(6). 269–278. 10 indexed citations

18.

Grem, Jean L., Lorrin Yee, David Venzon, Chris H. Takimoto, & Carmen J. Allegra. (1997). Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemotherapy and Pharmacology. 40(2). 117–125. 49 indexed citations

19.

Takimoto, Chris H., Raymond W. Klecker, William L. Dahut, et al.. (1994). Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 655(1). 97–104. 55 indexed citations

20.

Yee, Lorrin, et al.. (1992). Decreased Catabolism of Fluorouracil in Peripheral Blood Mononuclear Cells During Combination Therapy With Fluorouracil, Leucovorin, and Interferon -2a. JNCI Journal of the National Cancer Institute. 84(23). 1820–1825. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact